vs
Side-by-side financial comparison of Cambium Networks Corp (CMBM) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
Cambium Networks Corp is the larger business by last-quarter revenue ($40.3M vs $21.9M, roughly 1.8× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -17.9%, a 25.2% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs -23.2%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -27.2%).
Cambium Networks Corporation is an American manufacturer of wireless telecommunications equipment, including Enterprise WiFi, Network switch, Internet of Things, and fixed wireless broadband and Wi-Fi for enterprises products for Internet access. Publicly traded on the NASDAQ stock exchange, it spun out of Motorola in October 2011.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
CMBM vs CUE — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $40.3M | $21.9M |
| Net Profit | $-7.2M | $1.6M |
| Gross Margin | 36.6% | — |
| Operating Margin | -28.4% | 9.0% |
| Net Margin | -17.9% | 7.2% |
| Revenue YoY | -23.2% | 1292.3% |
| Net Profit YoY | 71.0% | 116.7% |
| EPS (diluted) | $-0.26 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $21.9M | ||
| Q3 25 | — | $2.1M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $421.0K | ||
| Q4 24 | $40.3M | $1.6M | ||
| Q3 24 | $44.7M | $3.3M | ||
| Q2 24 | $45.2M | $2.7M | ||
| Q1 24 | $47.1M | $1.7M |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-7.4M | ||
| Q2 25 | — | $-8.5M | ||
| Q1 25 | — | $-12.3M | ||
| Q4 24 | $-7.2M | — | ||
| Q3 24 | $-34.5M | $-8.7M | ||
| Q2 24 | $-14.2M | $-10.2M | ||
| Q1 24 | $-18.4M | $-12.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 36.6% | — | ||
| Q3 24 | 43.6% | — | ||
| Q2 24 | 32.5% | — | ||
| Q1 24 | 29.8% | — |
| Q4 25 | — | 9.0% | ||
| Q3 25 | — | -353.4% | ||
| Q2 25 | — | -292.3% | ||
| Q1 25 | — | -2921.4% | ||
| Q4 24 | -28.4% | — | ||
| Q3 24 | -69.6% | -264.2% | ||
| Q2 24 | -27.2% | -390.6% | ||
| Q1 24 | -33.1% | -737.8% |
| Q4 25 | — | 7.2% | ||
| Q3 25 | — | -346.6% | ||
| Q2 25 | — | -287.1% | ||
| Q1 25 | — | -2911.4% | ||
| Q4 24 | -17.9% | — | ||
| Q3 24 | -77.3% | -259.6% | ||
| Q2 24 | -31.5% | -382.7% | ||
| Q1 24 | -39.2% | -719.1% |
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.17 | ||
| Q4 24 | $-0.26 | — | ||
| Q3 24 | $-1.22 | $-0.17 | ||
| Q2 24 | $-0.51 | $-0.20 | ||
| Q1 24 | $-0.66 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $27.1M |
| Total DebtLower is stronger | $67.6M | — |
| Stockholders' EquityBook value | $-3.2M | $26.4M |
| Total Assets | $173.7M | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.1M | ||
| Q3 25 | — | $11.7M | ||
| Q2 25 | — | $27.5M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $22.5M | ||
| Q3 24 | — | $32.4M | ||
| Q2 24 | — | $30.0M | ||
| Q1 24 | — | $41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $67.6M | — | ||
| Q3 24 | $67.6M | $1.0M | ||
| Q2 24 | $68.9M | $2.0M | ||
| Q1 24 | $63.8M | $3.0M |
| Q4 25 | — | $26.4M | ||
| Q3 25 | — | $13.2M | ||
| Q2 25 | — | $18.2M | ||
| Q1 25 | — | $6.6M | ||
| Q4 24 | $-3.2M | $17.5M | ||
| Q3 24 | $1.9M | $25.4M | ||
| Q2 24 | $34.1M | $21.6M | ||
| Q1 24 | $45.0M | $30.0M |
| Q4 25 | — | $42.2M | ||
| Q3 25 | — | $31.6M | ||
| Q2 25 | — | $40.7M | ||
| Q1 25 | — | $22.3M | ||
| Q4 24 | $173.7M | $32.2M | ||
| Q3 24 | $194.3M | $44.8M | ||
| Q2 24 | $221.1M | $42.3M | ||
| Q1 24 | $219.8M | $54.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 36.12× | 0.04× | ||
| Q2 24 | 2.02× | 0.09× | ||
| Q1 24 | 1.42× | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.4M | $-1.1M |
| Free Cash FlowOCF − Capex | $-10.8M | — |
| FCF MarginFCF / Revenue | -26.8% | — |
| Capex IntensityCapex / Revenue | 1.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | $-21.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.1M | ||
| Q3 25 | — | $-9.0M | ||
| Q2 25 | — | $-3.4M | ||
| Q1 25 | — | $-8.2M | ||
| Q4 24 | $-10.4M | $-36.3M | ||
| Q3 24 | $8.9M | $-7.5M | ||
| Q2 24 | $2.4M | $-10.0M | ||
| Q1 24 | $-15.9M | $-9.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-3.4M | ||
| Q1 25 | — | $-8.3M | ||
| Q4 24 | $-10.8M | $-36.4M | ||
| Q3 24 | $6.8M | $-7.5M | ||
| Q2 24 | $87.0K | $-10.0M | ||
| Q1 24 | $-17.4M | $-9.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -116.5% | ||
| Q1 25 | — | -1976.7% | ||
| Q4 24 | -26.8% | -2309.3% | ||
| Q3 24 | 15.2% | -225.7% | ||
| Q2 24 | 0.2% | -376.2% | ||
| Q1 24 | -37.0% | -573.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 35.6% | ||
| Q4 24 | 1.1% | 4.2% | ||
| Q3 24 | 4.8% | 0.0% | ||
| Q2 24 | 5.1% | 0.4% | ||
| Q1 24 | 3.3% | 3.2% |
| Q4 25 | — | -0.68× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMBM
| Enterprise | $16.6M | 41% |
| Point To Multi Point | $16.4M | 41% |
| Other | $5.8M | 14% |
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
